GlassScriptPhysician profile
Frances Frederick Smith
NPI 1992016554
$906.32
in general payments reported to CMS, 2019-2025
16 companies · $142 in 2025
The $142 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $57.92 · 2021: $119 · 2022: $169 · 2023: $108 · 2024: $158 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $326.74 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $105.78 | 2020-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $101.11 | 2021-2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $96.82 | 2024-2025 | |
| Kaleo, INC. | $51.23 | 2022 | |
| Vertical Pharmaceuticals, LLC | $38.08 | 2019 | |
| Ironshore Pharmaceuticals INC. | $36.25 | 2019-2022 | |
| Seqirus USA INC | $26.22 | 2025 | Flucelvax |
| Biomarin Pharmaceutical INC. | $18.05 | 2025 | Voxzogo 1.2mg |
| Pfizer INC. | $17.48 | 2023 | |
| Sobi, INC | $16.38 | 2019 | |
| Genentech USA, INC. | $15.82 | 2020 | |
| Dermira, INC. | $15.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.02 | 2022 | |
| Phadia US INC. | $14.26 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.